公开(公告)号：WO0045854A2

公开(公告)日：2000-08-10

申请号：PCT/US0002004

申请日：2000-01-26

Applicant: SENORX INC

Inventor： BURBANK FRED H ,  LUBOCK PAUL ,  JONES MICHAEL L ,  FORCIER NANCY

IPC: A61B8/08 ,  A61B10/00 ,  A61B10/02 ,  A61B17/00 ,  A61B19/00 ,  A61K49/00

CPC classification number: A61B90/39 ,  A61B10/02 ,  A61B2017/00004 ,  A61B2090/3788 ,  A61B2090/3908 ,  A61B2090/3925 ,  A61B2090/3929 ,  A61B2090/3933 ,  A61B2090/395 ,  A61B2090/3975 ,  A61B2090/3987 ,  A61B2090/3995 ,  A61K49/006 ,  A61M37/0069

Abstract: Detectable markers that may be introduced into a cavity created by removal of a biopsy specimen to mark the location of the biopsy site so that it may be located in a subsequent medical/surgical procedure. The markers remain present in sufficient quantity to permit detection and location of the biopsy site at a first time point (e.g., 2 weeks) after introduction but clear from the biopsy site or otherwise not interfere with imaging of tissues adjacent the biopsy site at a second time point (e.g., 5-7 months) after introduction.

Abstract translation: 可以被引入通过去除活组织检查样本而产生的空腔中的可检测标记，以标记活组织检查部位的位置，使得其可以位于随后的医疗/外科手术中。 标记物以足够的量保持存在，以允许在引入后的第一时间点（例如2周）检测和定位活检部位，但是从活组织检查部位清除或以其他方式不干扰第二次活检部位附近的组织的成像 时间点（如5-7个月）。

公开(公告)号：WO9848838A8

公开(公告)日：2000-04-27

申请号：PCT/GB9801244

申请日：1998-04-28

Applicant: NYCOMED IMAGING AS ,  COCKBAIN JULIAN R M ,  SNOW ROBERT ALLEN ,  HENRICHS PAUL MARK ,  DELECKI DANIEL JOSEPH ,  SANDERSON WILLIAM ANTHONY ,  DESAI VINAY CHANDRAKANT ,  BACON EDWARD ,  HOLLISTER KENNETH ROBERT ,  HOHENSCHUH ERIC PAUL

Inventor： SNOW ROBERT ALLEN ,  HENRICHS PAUL MARK ,  DELECKI DANIEL JOSEPH ,  SANDERSON WILLIAM ANTHONY ,  DESAI VINAY CHANDRAKANT ,  BACON EDWARD ,  HOLLISTER KENNETH ROBERT ,  HOHENSCHUH ERIC PAUL

IPC: A61B1/00 ,  A61K31/765 ,  A61K41/00 ,  A61K49/00 ,  A61K49/04 ,  A61K49/12 ,  A61P35/00 ,  C07D311/80 ,  C08G65/02 ,  C09B23/00 ,  C09B69/10

CPC classification number: A61K49/0054 ,  A61K41/0033 ,  A61K41/0057 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0034 ,  A61K49/0036 ,  A61K49/0041 ,  A61K49/0043 ,  A61K49/0052 ,  A61K49/0056 ,  A61K49/006 ,  A61K49/0433 ,  A61K49/085 ,  A61K49/126

Abstract: This invention provides a physiologically tolerable light imaging contrast agent compound having a molecular weight in the range 500 to 500000 and containing at least two chromophores having delocalized electron systems as well as at least one polyalkylene oxide (PAO) moiety having a molecular weight in the range 60 to 100000.

Abstract translation: 本发明提供一种具有分子量在500至500000范围内且含有至少两个具有离域电子系统的发色团以及分子量在该范围内的至少一种聚环氧烷（PAO）部分的生理上可耐受的光成像造影剂化合物 60到100000。

公开(公告)号：WO99058159A1

公开(公告)日：1999-11-18

申请号：PCT/NL1999/000283

申请日：1999-05-07

IPC: A61F9/00 ,  A61F2/14 ,  A61F9/007 ,  A61K49/00 ,  A61P41/00

CPC classification number: A61K49/006

Abstract: The invention relates to a method for performing retinal membrane removal, wherein a retinal membrane is stained using at least one vital dye. The invention further relates to a staining composition for use in said method.

Abstract translation: 本发明涉及一种用于进行视网膜去除的方法，其中使用至少一种活性染料对视网膜进行染色。 本发明还涉及用于所述方法的染色组合物。

公开(公告)号：WO99055230A1

公开(公告)日：1999-11-04

申请号：PCT/US1999/009177

申请日：1999-04-27

IPC: G01R33/28 ,  A61B5/055 ,  A61K49/00 ,  A61K49/18 ,  C08B37/08

CPC classification number: C08B37/0072 ,  A61K49/006 ,  A61K49/1812

Abstract: Imaging agents containing hyaluronan (HA) and contrast agents. These imaging agents may include HA complexed with gadolinium, optionally with liposomes, and HA complexed with superparamagnetic iron oxides. A method of producing HA-based imaging agents includes mixing a solution of HA with a solution of contrast agent. A method of imaging using HA-based imaging agents includes using HA-based imaging agents to view cancer cells with magnetic resonance.

Abstract translation: 含有透明质酸（HA）和造影剂的成像剂。 这些成像剂可以包括与钆配合的HA，任选地与脂质体和与超顺磁性氧化铁配合的HA。 一种生产基于HA的成像剂的方法包括将HA溶液与造影剂溶液混合。 使用基于HA的成像剂进行成像的方法包括使用基于HA的成像剂来观察具有磁共振的癌细胞。

公开(公告)号：WO99031183A1

公开(公告)日：1999-06-24

申请号：PCT/EP1998/008282

申请日：1998-12-17

IPC: A61K49/00 ,  C08B37/00 ,  C08B37/18 ,  C09B69/00 ,  C09B69/10 ,  G01N33/52 ,  G01N33/58

CPC classification number: A61K49/006 ,  C08B37/0054 ,  G01N33/52

Abstract: The invention relates to novel dye-polysaccharide- or -cyclosaccaride-conjugates and the utilization thereof as a diagnostic, especially for determining the glomerular filtration rate in humans.

Abstract translation: 新染料 - 多糖缀合物或-Cyclosaccharid-和它们作为诊断剂的用途，特别是用于确定在人体中的肾小球滤过率。

公开(公告)号：WO98039653A1

公开(公告)日：1998-09-11

申请号：PCT/US1998/004422

申请日：1998-03-06

IPC: A01K67/027 ,  A61K49/00 ,  A61K51/10 ,  C07K14/705 ,  G01N33/68 ,  G01N33/53 ,  A01N37/18 ,  A23J1/00 ,  A61K38/00 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  C12N5/00 ,  C12N15/00

CPC classification number: A61K49/0004 ,  A01K67/027 ,  A61K49/006 ,  A61K51/1018 ,  C07K14/705 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2333/4722 ,  G01N2800/2821

Abstract: A method of perlecan isolation (from the EHS tumor) which produces "clean" (i.e., substantially "pure") perlecan is disclosed. Clean perlecan is thus produced in sufficient quantities for use in a number of different in vitro and in vivo assays. In addition, this isolation method exploits a newly discovered aggregating property of a SIMILAR 220 kDa heparan sulfate proteoglycan (HSPG) observed during gel filtration chromatography, which allows it to be effectively separated from non-aggregating perlecan. The method employs specific cation exchange, anion exchange, molecular sieve chromatography and immobilized GAG affinity chromatography. It is demonstrated that there are no other contaminating proteins in the perlecan and HSPG preparations, and that the perlecan core protein is intact. Improved, clean perlecan based, rodent models of fibrillar amyloid protein deposition, accumulation and/or persistence in tissues are disclosed.

Abstract translation: 公开了一种产生“干净”（即基本上“纯”）perlecan的perlecan分离方法（来自EHS肿瘤）。 因此，清洁的perlecan产生足够的量用于许多不同的体外和体内测定。 此外，这种分离方法利用了在凝胶过滤层析期间观察到的新近发现的类似于220kDa硫酸乙酰肝素蛋白多糖（HSPG）的聚集性质，其允许其与非聚集性perlecan有效分离。 该方法采用特异性阳离子交换，阴离子交换，分子筛色谱和固定化GAG亲和层析。 证明在perlecan和HSPG制剂中没有其他污染蛋白质，并且perlecan核心蛋白质是完整的。 公开了基于改进的，基于干扰素的，基于纤维状淀粉样蛋白沉积的啮齿动物模型，在组织中的积累和/或持续性。

公开(公告)号：WO1997047971A1

公开(公告)日：1997-12-18

申请号：PCT/US1997010078

申请日：1997-06-11

Applicant: ADVANCED RESEARCH & TECHNOLOGY INSTITUTE ,  KELLEY, Mark, R. ,  DUGUID, John, R. ,  EBLE, John, N.

Inventor： ADVANCED RESEARCH & TECHNOLOGY INSTITUTE

IPC: G01N33/574

CPC classification number: G01N33/5011 ,  A61K49/006 ,  C07K14/4747 ,  C07K16/40 ,  C12N9/22 ,  C12Q1/44 ,  G01N33/5091 ,  G01N33/573 ,  G01N33/57496 ,  G01N2333/914

Abstract: Disclosed are methods and compositions for identifying, monitoring and treating premalignant and malignant conditions in a human subject. The present invention further discloses methods and compositions for determining cells undergoing apoptosis, and for increasing the efficacy of a cancer therapy. The methods involve the use of apurinic/apyrimidinic endonuclease (APE), independently, as a marker for (pre)malignant conditions and for apoptosis. Also described are polyclonal antibody preparations for use in methods for detecting APE and methods for modulating expression susceptibility of cells to apoptosis.

Abstract translation: 公开了用于鉴定，监测和治疗人类受试者的恶化和恶化状况的方法和组合物。 本发明还公开了用于确定经历凋亡的细胞的方法和组合物，以及用于增加癌症疗法的功效。 所述方法包括使用无唾液酸/阿奇霉素内切核酸酶（APE），独立地用作（前）恶性条件和凋亡的标志物。 还描述了用于检测APE的方法的多克隆抗体制剂和调节细胞对凋亡的表达易感性的方法。

公开(公告)号：WO1997015225A1

公开(公告)日：1997-05-01

申请号：PCT/RU1996000306

申请日：1996-10-23

Applicant: ZEFIROV, Nikolai Serafimovich ,  AFANASIEV, Andrei Zakharovich ,  AFANASIEVA, Svetlana Vasilievna ,  BACHURIN, Sergei Olegovich ,  TKACHENKO, Sergei Evgenievich ,  GRIGORIEV, Vladimir Viktorovich ,  JUROVSKAYA, Marina Abramovna ,  CHETVERIKOV, Valery Pavlovich ,  BUKATINA, Elizaveta Evgenievna ,  GRIGORIEVA, Irina Vladimirovna

IPC: A51K31/475

CPC classification number: A61K49/006 ,  A61K31/437

Abstract: Hydrogenated pyrido(4,3-b)indoles of general formula (I) in which R , R and R have the meanings indicated in the description and have the properties of NMDA-antagonists and are suitable for use in treating neuro-degenerative disorders, especially Alzheimer's disease.

Abstract translation: 通式（I）的氢化吡啶并（4,3-b）吲哚，其中R 1，R 2和R 3具有说明书中所示的含义并具有NMDA-拮抗剂的性质，并且是合适的 用于治疗神经退行性疾病，特别是阿尔茨海默氏病。

公开(公告)号：WO1996036272A1

公开(公告)日：1996-11-21

申请号：PCT/US1996006238

申请日：1996-05-03

Applicant: POOLE, Thomas, A.

IPC: A61B03/16

CPC classification number: A61K9/0048 ,  A61B3/16 ,  A61K31/365 ,  A61K49/006 ,  A61K31/045 ,  A61K2300/00

Abstract: An applicator device (5) is disclosed directed to the controlled placement of a minute amount of fluorescein (25) is used as a staining agent to permit applanation tonometric measurements. The fluorescein is applied with a disinfectant to the tonometer lens using a special applicator (5). The disinfectant (25) evaporates leaving a thin film residue on the lens, which is subsequently redissolved in the tear film above the cornea (15). The foregoing de vice enhances the tonometer measurements while simplifying the process and reducing risk of entry of infective contaminates into the eye region. The invention also provides a device for disinfecting such multiple use articles as combs, earring posts and wires for pierced skin, manicure instruments, contact lens (both corrective and diagnostic), and thermometers.

Abstract translation: 公开了一种用于受控放置微量荧光素（25）的涂抹器装置（5），作为染色剂以允许压平质量测量。 使用特殊的涂抹器（5）将荧光素与眼压计透镜一起使用消毒剂。 消毒剂（25）蒸发，在透镜上留下薄膜残留物，其随后再溶解在角膜（15）上方的泪膜中。 上述方法增强了眼压计测量，同时简化了过程并降低了感染性污染物进入眼睛区域的风险。 本发明还提供了用于消毒诸如梳子，耳环柱和刺穿皮肤的电线，修指甲器具，隐形眼镜（校正和诊断）以及温度计的多种用途物品的装置。

公开(公告)号：WO2019068935A1

公开(公告)日：2019-04-11

申请号：PCT/EP2018/077355

申请日：2018-10-08

Applicant: ALFA INSTRUMENTS S.R.L.

Inventor： DAVID, Fabio

IPC: C09B11/20 ,  A61K49/00 ,  C07C309/49 ,  G01N33/68 ,  C07C309/46

CPC classification number: C09B11/20 ,  A61K49/0023 ,  A61K49/006 ,  C07C309/46 ,  C07C309/49 ,  G01N33/6839

Abstract: The present invention relates to dye molecules and to staining compositions comprising said dye molecules that are particularly suitable for selectively staining biological substrates, such as structures in the posterior eye segment and proteins. Said dye molecules may be used in ophthalmic surgery to help the surgeon to visualize structures in the posterior eye structures as well as in protein assays to determine one or more analytical parameter of a protein. The dye molecules have the following structure (I) wherein X represents an organic or inorganic cation; and R 1 represents a substituted or unsubstituted benzyl group. The present invention relates also to a new method for synthetizing dye molecules.